Clinical Trials Logo

Clinical Trial Summary

Prospective, multicenter, phase IV study, of real-life evidence destined to evaluate the feasibility and efficacy of performing a treatment adapted to PET-CT in patients with stage I and II DLBCL, without poor prognostic factors.


Clinical Trial Description

Patients older than 17 years of age, with no upper age limit with a de novo histological diagnosis of DLBCL, in stages I and II and without risk factors, will be included. All patients will have a baseline PET-CT and will undergo 3 cycles of R-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). A PET-CT will be performed on day 15-18 of the third cycle that will be centrally reviewed. Those patients with negative PET-CT (Deauville 1, 2 and 3) will receive an additional cycle of R-CHOP and will finish treatment. Patients who have PET-CT with a Deauville 4 score will complete a fourth cycle and then receive radiation therapy to the compromised site. Those patients with a Deauville score of 5 should receive rescue therapy, so they will be outside the protocol. A standardized follow-up of the patients included with tomographic controls will be carried out, evaluating OS (overall survival) and PFS (progression-free survival) at 3 years as the main objectives. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05078840
Study type Observational [Patient Registry]
Source Grupo Argentino de Tratamiento de la Leucemia Aguda
Contact Astrid Pavlovsky, Dr.
Phone 5491150613683
Email astridp@intramed.net
Status Recruiting
Phase
Start date June 1, 2021
Completion date June 1, 2025

See also
  Status Clinical Trial Phase
Withdrawn NCT03417765 - Safety, Tolerability, PK/PD of FE 203799 in Adults With Lymphomas Phase 1/Phase 2
Not yet recruiting NCT05979857 - Study of SP-3164 in Relapsed or Refractory Non-Hodgkin's Lymphoma Early Phase 1
Not yet recruiting NCT06343311 - T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) Phase 1/Phase 2